Annual Research & Review in Biology



13(4): 1-10, 2017; Article no.ARRB.33990 ISSN: 2347-565X, NLM ID: 101632869

# Antimicrobial Evaluation and Structure-Activity Relationship (SAR) of Some 1,ω-bis[4-Carboxy/Methoxycarbonyl/(Hydrazinecarbonyl) /Phenoxy]Alkanes

Nasser S. A. M. Khalil<sup>1\*</sup> and Noha M. Mohamed<sup>1</sup>

<sup>1</sup>Regional Center for Food and Feed, Agricultural Research Center, Giza, Egypt.

# Authors' contributions

This work was carried out in collaboration between both authors. Author NSAMK designed the study, managed literature searches, performed and managed the chemical synthesis, wrote the protocol and wrote the first draft of the manuscript. Author NMM managed the elemental analyses, spectral data (IR data, <sup>1</sup>HNMR data) and antimicrobial evaluation of the study. Both authors read and approved the final manuscript.

### Article Information

DOI: 10.9734/ARRB/2017/33990 <u>Editor(s):</u> (1) David E. Martin, Martin Pharma Consulting, LLC, Shawnee, OK, USA. (2) George Perry, Dean and Professor of Biology, University of Texas at San Antonio, USA. (2) George Perry, Dean and Professor of Biology, University of Texas at San Antonio, USA. (2) George Perry, Dean and Professor of Biology, University of Texas at San Antonio, USA. (1) Abhishek Kumar, Nitte University, India. (2) Nevin Turan, Muş Alparslan University, Turkey. Complete Peer review History: <u>http://www.sciencedomain.org/review-history/19452</u>

Original Research Article

Received 8<sup>th</sup> May 2017 Accepted 29<sup>th</sup> May 2017 Published 10<sup>th</sup> June 2017

# ABSTRACT

A series of some 1, $\omega$ -bis[4-carboxy/methoxycarbonyl/(hydrazinecarbonyl)/phenoxy]alkanes were synthesized and evaluated for their antimicrobial activity against different strains of Gram-positive bacteria (*Bacillus subtilis* RCMB 101-001 and *Staphylococcus aureus* RCMB 106-001 (1)), Gramnegative bacteria (*Pseudomonas aeruginosa* RCMB 102-002 and *Escherichia coli* RCMB 103-001), yeast (*Candida albicans* RCMB 005003) and fungi (*Aspergillus fumigates* RCMB 002008 (1), *Penicillium italicum* RCMB 001018 (1) and *Syncephalastrum racemosum* RCMB 016001). The screening results revealed that all the tested compounds exhibited different inhibitory effects against different organisms. Thus, compounds 1, 4, exhibited inhibitory effects against all the test organisms, compounds 5, 7 exhibited inhibitory effects against six of total eight test organisms. Some tested

<sup>\*</sup>Corresponding author: E-mail: nasserkhalil\_23@hotmail.com;

Khalil and Mohamed; ARRB, 13(4): 1-10, 2017; Article no.ARRB.33990

compounds, at specific concentrations, showed the same or higher inhibitory effects against some test organisms, compared to standard antimicrobial agents, at the same concentrations. Thus, while compound 1 gave the same inhibitory effect against Aspergillus fumigatus RCMB 002008 (1) (at concentrations 1.0, 2.5 and 5.0 mg/mL) as Tebinafine (standard antifungal agent), it showed much higher inhibitory effect against Syncephalastrum racemosum RCMB 016001 (at concentrations 2.5 and 5.0 mg/mL) and Candida albicans RCMB 005003 (at concentrations 1, 2.5 and 5 mg/mL). Compound 7, also, compared to Terbinafine, while revealed the same inhibitory effect, against Penicillium italicum RCMB 001018 (1) (at concentrations 1.0, 2.5 and 5.0 mg/mL), it revealed higher inhibitory effect against Aspergillus fumigatus RCMB 002008 (1) (at concentration 5.0 mg/mL), Syncephalastrum racemosum RCMB 016001 (at concentration 2.5 mg/mL) and Candida albicans RCMB 005003 (at concentration 5.0 mg/mL). Compared to the standard antibacterial Chloramphenicol, compound 7 revealed the same inhibitory effect against Staphylococcus aureus RCMB 106-001 (1) (at concentrations 1.0, 2.5 and 5 mg/mL) and Escherichia coli RCMB 103-001 (at concentrations 1.0, 2.5 and 5 mg/mL). The structure-activity relationship was investigated via studying the effect of the aliphatic spacer length between the two ethereal oxygen atoms as well as the effect of functional group attached to the two carbonyl groups (hydroxy/methoxy/hydrazine) on the inhibitory effect of the titled compounds.

Keywords: Antimicrobial activity; structure-activity relationship;  $1,\omega$ -bis(organic acids);  $1,\omega$ -bis(organic esters);  $1,\omega$ -bis(hydrazides);  $1,\omega$ -bis(phenoxyalkanes).

# 1. INTRODUCTION

Many Organic acids and esters that are existed by nature, at different concentrations, in many types of foods and beverages, are potent antimicrobial agents and used principally in acidic foods as inhibitors to yeasts, molds and bacteria at pH above 4.5 [1].

Hydrazides and compounds related are described as building blocks of various heterocyclic rings [2] and important starting materials for a wide range of derivatives utilizable in pharmaceutical products and surfactants, so, they are useful medicaments, especially, in the treatment of inflammatory and autoimmune diseases, osteoarthritis, respiratory diseases, tumors, cachexia, cardiovascular diseases, fever, hemorrhage and sepsis [3]. Hydrazide derivatives exhibited anthelmintic [4], antifungal [5], antiviral bacteriostatic [5-8], antiparasite [5,9], [6], [10-13], antitumor antituberculous [3,14], anticonvulsant [15], psychotropic [5], and insecticidal [16] activities. While some heterocyclic hydrazides are useful as antifertility agents in rats and pigeons [17], others, find useful applications, as active ingredients, in deodorant compositions that can be used for removal of offensive odor [18].

Development of antibiotic-resistant bacterial and fungal strains over recent decades resulted in substantial need of new classes of antimicrobial agents. So, herein, and in continuation of our program [14,19-38] directed to synthesize and biologically evaluate some promising candidates of new organic compounds, the antimicrobial evaluation and structure-activity relationship of an interesting new class of  $1,\omega$ -bis[4-carboxy/methoxycarbonyl/(hydrazinecarbonyl)/p-henoxy]alkanes are studied.

# 2. MATERIALS AND METHODS

# 2.1 Synthesis

## 2.1.1 General

Compounds **1**, **2**, **4**, **5**, **7** (Fig. 1) were synthesized as reported [27] and identified by melting points (determined using Stuart<sup>®</sup> meting point apparatus SMP3 and are uncorrected), IR spectra (recorded in KBr discs using Perkin-Elmer 1430 spectrometer), <sup>1</sup>H NMR spectra (recorded at 300 MHz with a Varian Mercury 300 spectrometer), mass spectra (measured on Shimadzu GCMS-QP2010 Plus spectrometer, with an El ionization mode and 70 eV electronic voltage) and elemental analyses (carried out at the Micro Analytical Center, Cairo University, Giza, Egypt).

### 2.1.2 Synthesis of 1,ω-bis(4-carboxyphenoxy)alkanes 1, 2. General procedure [27]

A mixture of each of compounds **4**, **5** (5 mmol) in aq KOH (10%, 20 mL) was heated at reflux temperature for 24 h and left to cool. The non reacted bis(ester) was extracted with DCM (3 x 20 mL) and discarded. The aq phase was diluted with concd HCL (3-7 mL) and the Khalil and Mohamed; ARRB, 13(4): 1-10, 2017; Article no.ARRB.33990



1,ω-Bis(4-carboxyphenoxy)alkanes





1,ω-Bis(4-methoxycarbonylphenoxy)alkanes

1, 4 X= 0
2, 5, 7 X= (CH <sub>2</sub> )
3, 6, 8 X= (CH <sub>2</sub> ) <sub>2</sub>

#### 1,ω-Bis[4-(hydrazinecarbonyl)phenoxy]alkanes

#### Fig. 1. 1, w-bis[4-carboxy/methoxycarbonyl/(hydrazinecarbonyl)/phenoxy]alkanes

obtained solid was collected by filtration and washed successively with water (3 x 100 mL) and MeOH (3 x 10 mL). The product was dried and recrystallized from DMF/MeOH.

#### 2.1.2.1 1,2-Bis(4-carboxyphenoxy)ethane (1) [27]

Yield 1.36 g (90%); colorless crystals, mp 350°C. IR: 3082-2557 (br), 3082, 2951, 2885, 2827, 2678, 2557, 1682, 1605, 1578, 1512, 1481, 1435, 1304, 1254, 1165, 1119, 1045, 945, 845, 768, 691, 644, 629, 552, 505, 478, 421. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>)  $\delta$  4.41 (s, 4H, OCH<sub>2</sub>CH<sub>2</sub>), 7.07 (d, 4H, *J*= 8.9 Hz, ArH), 7.90 (d, 4H, *J*= 8.9 Hz, ArH), 12.59 (br, 2H, D<sub>2</sub>O exchangeable OH) Anal. Calcd for C<sub>16</sub>H<sub>14</sub>O<sub>6</sub> (302.3): C, 63.57; H, 4.67. Found: C, 63.59; H, 4.65.

#### 2.1.2.2 1,3-Bis(4-carboxyphenoxy)propane (2) [27]

Yield 1.38 g (87%); colorless crystals, mp 327-328°C. Anal. Calcd for  $C_{17}H_{16}O_6$  (316.3): C, 64.55; H, 5.10. Found: C, 64.51; H, 5.18.

#### <u>2.1.3 Synthesis of 1,ω-bis(4-methoxycarbony-</u> <u>Iphenoxy)alkanes 4, 5. General</u> <u>procedure [27]</u>

To a solution of the K-salt of methylparaben (100 mmol) in dry DMF (75 mL) was added appropriate dihalo compound (50 mmol). The reaction mixture was then heated at reflux temperature for 15 min (during which time KCl

was separated) and poured over cold water containing cruched ice (150 mL). The formed precipitate was collected by filtration, washed with cold water (3 x 150 mL) followed by MeOH (3 x 50 mL), dried and recrystallized from DMF/MeOH.

#### 2.1.3.1 1,2-Bis(4-methoxycarbonylphenoxy)ethane (4) [27]

Yield 4.13 g (25%); colorless crystals, mp 163-164°C. IR: 3055, 3017, 2959, 2893, 2843, 1720, 1609, 1508, 1481, 1435, 1346, 1315, 1254, 1215, 1192, 1169, 1111, 1042, 1011, 953, 856, 768, 698, 644, 517, 471, 421. <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\overline{0}$  3.89 (s, 6H, COOCH<sub>3</sub>), 4.40 (s, 4H, OCH<sub>2</sub>CH<sub>2</sub>O), 6.97 (d, 4H, *J*= 9.0 Hz, ArH), 8.01 (d, 4H, *J*= 9.0 Hz, ArH). Ms: m/z= 330 (M+). Anal. Calcd for C<sub>18</sub>H<sub>18</sub>O<sub>6</sub> (330.3): C, 65.45; H, 5.49. Found: C, 65.49; H, 5.38.

#### 2.1.3.2 1,3-Bis(4-methoxycarbonylphenoxy)propane (5) [27]

Yield 8.95 g (52%); colorless crystals, mp 136-138°C. Anal. Calcd for  $C_{19}H_{20}O_6$  (344.4): C, 66.27; H, 5.85. Found: C, 66.23; H, 5.91

#### 2.1.4 Synthesis of 1,3-bis[4-(hydrazinecarbonyl)phenoxy]propane (7) [27]

A mixture of the 1,3-bis(ester) **5** (25 mmol) and hydrazine monohydrate (100 mL) was heated at reflux temperature for 4 h during which time the product precipitated from the mixture. After cooling to room temperature, water was added

(100 mL) and the formed precipitate was collected by filtration, washed succisively with water (3 x 100 mL), MeOH (3 x 25 mL) and chloroform (3 x 25 mL), dried and recrystallized from DMF. Yield 7.92 g (92%); colorless crystals, mp 246-247°C. IR: 3298, 3275, 3186, 3071, 2951, 2882, 1655, 1635, 1609, 1574, 1539, 1504, 1466, 1423, 1385, 1335, 1304, 1250, 1196, 1173, 1119, 1053, 968, 883, 849, 775, 721, 664, 625, 521, 482, 421. <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 1.88 (quint, 2H, J= 5.3 Hz, OCH<sub>2</sub>CH<sub>2</sub>), 4.08 (t, 4H, J= 5.3 Hz, OCH<sub>2</sub>CH<sub>2</sub>O), 4.42 (s, 4H, D<sub>2</sub>O exchangeable NH<sub>2</sub>), 6.97 (d, 4H, J= 8.9 Hz, ArH), 7.79 (d, 4H, J= 8.9 Hz, ArH), 9.59 (s, 2H, D<sub>2</sub>O exchangeable NH). Anal. Calcd for  $C_{17}H_{20}N_4O_4$  (344.4): C, 59.29; H, 5.85; N, 16.27. Found: C, 59.22; H, 5.79; N, 16.22.

# 2.2 Antimicrobial Evaluation of Compounds 1, 2, 4, 5, 7

The in vitro antimicrobial screening of compounds 1, 2, 4, 5, 7 was carried out using the diffusion agar technique [39,40]. The test organisms were obtained from the culture of the Regional Center for Mycology and Biotechnology (RCMB), Faculty of Science, Al-Azhar University, Cairo, Egypt. Compounds 1, 2, 4, 5, 7 as well as standard antimicrobial agents (Chloramphenicol Terbinafine were used as standard and antibacterial and antifungal agents, respectively) were dissolved in DMSO (5 mg/mL). Further dilutions of the tested compounds and standard agents were prepared at the required quantities of 5, 2.5 and 1 mg/mL concentrations. All the compounds were tested for their in vitro growth inhibitory activity against two Gram-positive bacterial strains (Bacillus subtilis RCMB 101-001 and Staphylococcus aureus RCMB 106-001 (1)), Gram-negative bacterial two strains (Pseudomonas aeruginosa RCMB 102-002 and Escherichia coli RCMB 103-001), one yeast strain (Candida albicans RCMB 005003) and three mould strains (Aspergillus fumigatus RCMB 002008 (1), Penicillium italicum RCMB 001018 (1) and Syncephalastrum racemosum RCMB 016001). The antimicrobial activities were expressed as the diameter of the inhibition zones (Tables 1-3).

# 3. RESULTS AND DISCUSSION

Table (1) illustrates the antimicrobial activity  $1,\omega$ bis(4-carboxyphenoxy) alkanes (**1-3**). Compound **1**, namely, 1,2-bis(4-carboxyphenoxy)ethane, exhibited inhibitory effect against all the test organisms. Thus, it revealed inhibitory effects against Aspergillus fumigatus RCMB 002008 (1) (at concentrations 1.0, 2.5 and 5.0 mg/mL), Penicillium italicum RCMB 001018 (1) (at concentration 5.0 mg/mL), Syncephalastrum racemosum RCMB 016001 (at concentrations 2.5 and 5.0 mg/mL), Candida albicans RCMB 005003 (at concentrations 1.0, 2.5 and 5.0 mg/mL), Staphylococcus aureus RCMB 106-001 (1) (at concentration 5.0 mg/mL), Pseudomonas aeruginosa RCMB 102-002 (at concentrations 2.5 and 5.0 mg/mL), Bacillus subtilis RCMB 101-001 (at concentration 5.0 mg/mL) and Escherichia coli RCMB 103-001 (at concentrations 2.5 and 5.0 mg/mL).

Compound 2. namely, 1.3-bis(4carboxyphenoxy)propane (Table 1), revealed inhibitory effect against six of total eight test organisms. Thus, it revealed inhibitory effects against Aspergillus fumigatus RCMB 002008 (1) (at concentrations 1.0, 2.5 and 5.0 mg/mL), Penicillium italicum RCMB 001018 (1) (at concentration 5.0 mg/mL), Candida albicans RCMB 005003 (at concentration 5.0 mg/mL), Staphylococcus aureus RCMB 106-001 (1) (at concentrations 1.0, 2.5 and 5.0 mg/mL), Pseudomonas aeruginosa RCMB 102-002 (at concentration 5.0 mg/mL) and Bacillus subtilis RCMB 101-001 (at concentrations 2.5 and 5.0 mg/mL), while, it revealed no inhibitory effect against Syncephalastrum racemosum RCMB 016001 and Escherichia coli RCMB 103-001.

The antimicrobial inhibitory effect of compound 3, namely, 1.4-bis(4-carboxyphenoxy)butane, was reported [27]. Thus, Compound 3, as previously reported [27], against the current test organisms, revealed inhibitory effect against six of eight (it was also reported to give inhibitory effect against salmonella typhi at concentrations 2.5, 5.0 mg/mL). Compound 3 revealed inhibitory effects against Aspergillus fumigatus RCMB 002008 (1) (at concentrations 1.0, 2.5 and 5.0 mg/mL), Syncephalastrum racemosum RCMB 016001 (at concentrations 1.0, 2.5 and 5.0 mg/mL), Candida albicans RCMB 005003 (at concentration 5.0 mg/mL), Staphylococcus aureus RCMB 106-001 (1) (at concentration 5.0 mg/mL), Pseudomonas aeruginosa RCMB 102-002 (at concentration 5.0 mg/mL), Escherichia coli RCMB 103-001 (at concentration 5.0 mg/mL), while, it revealed no inhibitory effect against Penicillium italicum RCMB 001018 (1) and Bacillus subtilis RCMB 101-001.

Having shorter spacer between the aromatic rings, compound **1** showed much broad spectrum, than those of compounds **2** and **3**, as it

# Table 1. Antimicrobial activity of $1,\omega$ -bis(4-carboxyphenoxy)alkanes (1-3) compared to standard antimicrobial agents



Test Organisms	Compound														
	<b>1</b> <sup>a</sup>			<b>2</b> <sup>a</sup>			<b>3</b> a,	d		St. <sup>b</sup>			St	t. <sup>c</sup>	
	Concentration (mg/mL)														
	1	2.5	5	1	2.5	5	1	2.5	5	1	2.5	5	1	2.5	5
<i>A. fumigatus</i> RCMB 002008 (1)	+	+	+	+	+	+	+	+	++	0	0	0	+	+	+
<i>P. italicum</i> RCMB 001018 (1)	0	0	+	0	0	+	0	0	0	0	+	+	+	+	+
S. racemosum RCMB 016001	0	+	++	0	0	0	+	+	++	+	+	+	0	0	+
<i>C. albicans</i> RCMB 005003	+	+	+	0	0	+	0	0	+	0	+	+	0	0	0
S. <i>aureus</i> RCMB 106-001 (1)	0	0	+	+	+	+	0	0	+	+	+	+	+	+	++
<i>P. aeruginosa</i> RCMB 102-002	0	+	+	0	0	+	0	0	+	+	+	+	0	0	0
<i>B. subtilis</i> RCMB 101-001	0	0	+	0	+	+	0	0	0	++	++	++	0	0	+
<i>E. coli</i> RCMB 103-	0	+	+	0	0	0	0	0	+	+	+	+	+	+	+

Note: The test was done using the diffusion agar technique. Inhibition values = 0.1-0.5 cm beyond control = +; Inhibition values = 0.6-1.0 cm beyond control = ++; Inhibition values = 1.0-1.5 cm beyond control = +++; 0 = Not detected.

<sup>a</sup>100  $\mu$ L of each conc. was tested (1.0, 2.5, 5.0 mg/mL); Well diameter = 0.6 cm.

<sup>b</sup>St.: Reference standard; Chloramphenicol was used as a standard antibacterial agent.

<sup>c</sup>St.: Reference standard; Terbinafine was used as a standard antifungal agent.

<sup>d</sup>Activity of compound **3** was reported [27]

showed inhibitory effect against all the test organisms at concentration 5.0 mg/mL, while, compounds **2** and **3**, with longer spacer, revealed inhibitory effect against six of total eight test organisms, at the same concentration. On the other hand, compound **3**, with longer spacer, exhibited higher inhibitory effect against *Aspergillus fumigatus* RCMB 002008 (1) (at concentration 5.0 mg/mL) and *Syncephalastrum racemosum* RCMB 016001 (at concentration 1.0 mg/mL).

Compound **4**, namely, 1,2-bis(4methoxycarbonylphenoxy)ethane (Table 2), showed inhibitory effect against all the test organisms. Thus, it revealed inhibitory effects against *Aspergillus fumigatus* RCMB 002008 (1) (at concentration 5.0 mg/mL), *Penicillium italicum* RCMB 001018 (1) (at concentration 5.0 mg/mL), Syncephalastrum racemosum RCMB 016001 (at concentration 5.0 mg/mL), Candida albicans RCMB 005003 (at concentration 5.0 mg/mL), Staphylococcus aureus RCMB 106-001 (1) (at concentrations 2.5 and 5.0 mg/mL), Pseudomonas aeruginosa RCMB 102-002 (at concentrations 2.5 and 5.0 mg/mL), Bacillus subtilis RCMB 101-001 (at concentrations 1.0, 2.5 and 5.0 mg/mL) and Escherichia coli RCMB 103-001 (at concentrations 2.5 and 5.0 mg/mL).

Compound **5**, namely, 1,3-bis(4methoxycarbonylphenoxy)propane (Table 2), revealed inhibitory effect against seven of total eight test organisms. Thus, it revealed inhibitory effects against *Aspergillus fumigatus* RCMB 002008 (1) (at concentration 5.0 mg/mL), *Penicillium italicum* RCMB 001018 (1) (at

# Table 2. Antimicrobial activity of 1,ω-bis(4-methoxycarbonylphenoxy)alkanes (4-6) compared to standard antimicrobial agents



Test	Compound														
Organisms	Con	npoun	d 4 <sup>a</sup>	Coi	Compound 5 <sup>a</sup> Compound 6 <sup>a,d</sup>								St. <sup>c</sup>		
				Concentration (mg/mL)											
	1	2.5	5	1	2.5	5	1	2.5	5	1	2.5	5	1	2.5	5
A. <i>fumigatus</i> RCMB 002008 (1)	0	0	+	0	0	+	0	+	+	0	0	0	+	+	+
<i>P. italicum</i> RCMB 001018 (1)	0	0	+	0	+	+	+	+	+	0	+	+	+	+	+
S. racemosum RCMB 016001	0	0	+	+	+	+	+	+	++	+	+	+	0	0	+
<i>C. albicans</i> RCMB 005003	0	0	+	+	+	++	+	+	++	0	+	+	0	0	0
S. aureus RCMB 106- 001 (1)	0	+	+	+	+	+	0	+	+	+	+	+	+	+	++
<i>P. aeruginosa</i> RCMB 102- 002	0	+	+	+	+	+	0	0	0	+	+	+	0	0	0
<i>B. subtilis</i> RCMB 101- 001	+	+	++	0	0	0	+	+	+	++	++	++	0	0	+
<i>E. coli</i> RCMB 103-001	0	+	+	+	+	+	0	+	++	+	+	+	+	+	+

Note: The test was done using the diffusion agar technique. Inhibition values = 0.1-0.5 cm beyond control = +; Inhibition values = 0.6-1.0 cm beyond control = ++; Inhibition values = 1.0-1.5 cm beyond control = +++; 0 = Not detected.

<sup>a</sup>100  $\mu$ L of each conc. was tested (1.0, 2.5, 5.0 mg/mL); Well diameter = 0.6 cm.

<sup>b</sup>St.: Reference standard; Chloramphenicol was used as a standard antibacterial agent.

<sup>c</sup>St.: Reference standard; Terbinafine was used as a standard antifungal agent.

<sup>d</sup>Activity of compound **6** was reported [27]

concentrations 2.5 and 5.0 mg/mL), Syncephalastrum racemosum RCMB 016001 (at concentrations 1.0, 2.5 and 5.0 mg/mL), Candida albicans RCMB 005003 (at concentrations 1.0, 2.5 and 5.0 mg/mL), Staphylococcus aureus RCMB 106-001 (1) (at concentrations 1.0, 2.5 and 5.0 mg/mL), Pseudomonas aeruginosa RCMB 102-002 (at concentrations 1.0, 2.5 and 5.0 mg/mL) and Escherichia coli RCMB 103-001 (at concentrations 1.0, 2.5 and 5.0 mg/mL), while, it revealed no inhibitory effect against *Bacillus subtilis* RCMB 101-001.

The antimicrobial inhibitory effect of compound **6**, namely, 1,4-bis(4-methoxycarbonylphenoxy)butaane, was reported [27]. Thus, Compound **6**, as previously reported [27], versus the current eight test organisms, revealed inhibitory effect against seven of them (it also exhibited no inhibitory effect against *Salmonella typhi* at concentrations

# NH NH<sub>2</sub> 7,8 NH<sub>2</sub>

Table 3. Antimicrobial activity of 1,ω-bis[4-(hydrazinecarbonyl)phenoxy]alkanes (7, 8) compared to standard antimicrobial agents

Test organisms	Compound											
-	Com	pound 7	7 <sup>a</sup>	Con	npound	<b>18<sup>a, d</sup></b>	St.⁵			St. <sup>c</sup>		
					Conc	entration						
	1	2.5	5	1	2.5	5	1	2.5	5	1	2.	5
											5	
A. fumigatus	+	+	++	+	+	+	0	0	0	+	+	+
RCMB 002008 (1)				•								
<i>P. italicum</i> RCMB 001018 (1)	+	+	+	0	+	+	0	+	+	+	+	+
S. racemosum	0	+	+	0	+	+	+	+	+	0	0	+
RCMB 016001												
C. albicans	0	0	+	++	++	+++	0	+	+	0	0	0
RCMB 005003												
S. aureus RCMB 106-001 (1)	+	+	+	0	+	+	+	+	+	+	+	++
P. aeruginosa	0	0	0	0	0	+	+	+	+	0	0	0
RCMB 102-002												
B. subtilis RCMB	0	+	+	+	+	+	++	++	+	0	0	+
101-001									+			
<i>E. coli</i> RCMB 103-	+	+	+	0	+	+	+	+	+	+	+	+

Note: The test was done using the diffusion agar technique. Inhibition values = 0.1-0.5 cm beyond control = +; Inhibition values = 0.6-1.0 cm beyond control = ++; Inhibition values = 1.0-1.5 cm beyond control = ++; 0 = Not

detected.

<sup>a</sup>100 μL of each conc. was tested (1.0, 2.5, 5.0 mg/mL); Well diameter = 0.6 cm.
<sup>b</sup>St.: Reference standard; Chloramphenicol was used as a standard antibacterial agent.
<sup>c</sup>St.: Reference standard; Terbinafine was used as a standard antifungal agent.
<sup>d</sup>Activity of compound **8** was reported [27]

1.0, 2.5 and 5.0 mg/mL). Compound 6 revealed inhibitory effects against Aspergillus fumigatus RCMB 002008 (1) (at concentrations 2.5 and 5.0 mg/mL), Penicillium italicum RCMB 001018 (1) (at concentrations 1.0, 2.5 and 5.0 mg/mL), Syncephalastrum racemosum RCMB 016001 (at concentrations 1.0, 2.5 and 5.0 mg/mL), 005003 Candida albicans RCMB (at concentrations 1.0, 2.5 and 5.0 mg/mL), Staphylococcus aureus RCMB 106-001 (1) (at concentrations 2.5 and 5.0 mg/mL), Bacillus subtilis RCMB 101-001 at concentrations (1.0, 2.5 and 5.0 mg/mL) and Escherichia coli RCMB 103-001 (at concentrations 2.5 and 5.0 mg/mL), while, it revealed no inhibitory effect against *Pseudomonas aeruginosa* RCMB 102-002.

It could be noted that, compound **4**, with short spacer, showed much broad spectrum, than those of compounds **5** and **6**, as it showed inhibitory effect against all the test organisms at concentration 5.0 mg/mL, while, compounds **5** and **6**, with longer spacer, revealed inhibitory effect against seven of total eight test organisms. At concentration 5 mg/mL, compound **4**, with short spacer, revealed its most inhibitory effect against *Bacillus subtilis* RCMB 101-001, compound **5**, with medium spacer revealed its

most potent inhibitory effect against *Candida albicans* RCMB 005003, compound **6** with longer spacer revealed its most potent inhibitory effect against *Syncephalastrum racemosum RCMB* 016001, *Candida albicans* RCMB 005003 and *Escherichia coli* RCMB 103-001.

1,3-bis[4-Compound 7, namely, (hydrazinecarbonyl)phenoxy]propane (Table 3), exhibited inhibitory effect against seven of total eight test organisms. Thus, it revealed inhibitory effects against Aspergillus fumigatus RCMB 002008 (1) (at concentrations 1.0, 2.5 and 5.0 mg/mL), Penicillium italicum RCMB 001018 (1) (at concentrations 1.0, 2.5 and 5.0 mg/mL), Syncephalastrum racemosum RCMB 016001 (at concentrations 2.5 and 5.0 mg/mL), Candida albicans RCMB 005003 (at concentration 5.0 mg/mL), Staphylococcus aureus RCMB 106-001 (1) (at concentrations 1.0, 2.5 and 5.0 mg/mL), Bacillus subtilis RCMB 101-001 (at concentrations 2.5 and 5.0 mg/mL) and Escherichia coli RCMB 103-001 (at concentrations 1.0, 2.5 and 5.0 mg/mL), while, it inhibitory effect revealed no against Pseudomonas aeruginosa RCMB 102-002.

Compared to the previously reported activity of 1,4-bis[4-(hydrazinecarbonyl)phenoxy]butane 8 [27], compound 7, with shorter spacer showed lower inhibitory effect against Candida albicans RCMB 005003 (at concentrations 1.0, 2.5 and 5.0 mg/mL), Pseudomonas aeruginosa RCMB 102-002 (at concentration 5.0 mg/mL) and Bacillus subtilis RCMB 101-001 (at concentration 1 mg/mL). On the other hand, compound 7 gave higher inhibitory effect against Aspergillus fumigates RCMB 002008 (at concentration 5.0 mg/mL), Penicillium italicum RCMB 001018 (1) (at concentration 1.0 mg/mL), Staphylococcus aureus RCMB 106-001 (1) (at concentration 1.0 mg/mL) and Escherichia coli RCMB 103-001 (at concentration 1.0 mg/mL), compared to compound 8.

Compared to standard antimicrobial agents, while some compounds, at specific concentrations showed the same inhibitory effect against some organisms, at other concentrations, they revealed higher inhibitory effect against other organisms. For example, while compound **1** gave the same inhibitory effect against *Aspergillus fumigatus* RCMB 002008 (1) (at concentrations 1.0, 2.5 and 5.0 mg/mL) as Tebinafine (standard antifungal agent), it showed much higher inhibitory effect against *Syncephalastrum racemosum* RCMB 016001 (at concentrations 2.5 and 5.0 mg/mL) and Candida albicans RCMB 005003 (at concentrations 1, 2.5 and 5 mg/mL). Compound 7, also, compared to Terbinafine, while revealed the same inhibitory effect, against Penicillium italicum RCMB 001018 (1) (at concentrations 1.0, 2.5 and 5.0 mg/mL), it revealed higher inhibitory effect against Aspergillus fumigatus RCMB 002008 (1) (at concentration 5.0 mg/mL), Syncephalastrum racemosum RCMB 016001 (at concentration 2.5 mg/mL) and Candida albicans RCMB 005003 (at concentration 5.0 mg/mL). Compared to the standard antibacterial Chloramphenicol, compound 7 revealed the same inhibitory effect against Staphylococcus aureus RCMB 106-001 (1) (at concentrations 1.0, 2.5 and 5 mg/mL) and Escherichia coli RCMB 103-001 (at concentrations 1.0, 2.5 and 5 mg/mL).

### 4. CONCLUSION

The biologically evaluated  $1,\omega$ -bis[4-carboxy/methoxycarbonyl/(hydrazinecarbonyl)/phenoxy]alkanes **1**, **2**, **4**, **5**, **7** were found to possess antimicrobial activity against wide spread microorganisms (Gram-postive bacteria, Gram-negative bacteria, yeast and fungi). The potency of the evaluated compounds depends on the functional group attached to the carbonyl ring as well as the spacer length between the two aromatic rings. Some of the evaluated compounds, versus some organisms, were found to be either as potent as or more potent than the standard antimicrobial agents, at specific concentrations.

## COMPETING INTERESTS

Authors have declared that no competing interests exist.

#### REFERENCES

- Stratford M, Eklund T. Organic acids and esters. In: Food preservatives; Chapter 4, Springer Link. 2003;48-49.
- Polanc S. Recent application of hydrazides and related compounds for the synthesis of heterocycles. Targets Heterocycl. Syst. 1999;3:33-91.
- Broadhurst MJ, Johnson, WH, Walter DS. Preparation of hydroxycarbamoylalkylcarboxylic acid azacyclic hydrazides as TNF-α inhibitors. PTC Int. Appl. WO 00 35,885; 2000.
- 4. Cavier R, Rips R. Antianthelminate effect of thioamides. J. Med. Chem. 1965;8:706-9.

- Dutta MM, Goswami BN, Kataky JCS. Studies on biologically active heterocycles. Part I. Synthesis and antifungal activity of some new aroyl hydrazones and 2, 5-disubstituted-1,3,4-oxadiazoles. J. Heterocyclic Chem. 1986;23(3):793-795.
- Sengupta AK, Bhatnagar A. Synthesis and antimicrobial screening of [[1-(4methyl/chlorophenyl)-1*H*-tetrazolo-5-yl]thio-]acetic acid [*N*-substituted-phenyl) methylene]hydrazides]. J. Indian Chem. Soc. 1987; LXIV:616-619.
- Frman PH, Straub H. Heterocyclic hydrazide derivatives of monocyclic γlactam antibiotics, U.S. US 5,318,963; 1994.
- Markham PN, Klyachko EA, Crich D, Jaber MR, Johnson ME, Mulhearn DC, Neyfakh AA. Bactericidal antimicrobial methods and compositions using acyl hydrazides, oxyamides, and 8-hydroxyquinolines as antibiotic potentiators for treatment of Gram-positive infections. PCT Int. Appl. WO 01 70, 213; 2001.
- Troeberg L, Chen X, Flaherty TM, Morty RE, Cheng M, Hua H, Springer C, Mc Kerrow JH, Kenyon GL, Lonsdale-Eccles JD, Coetzer THT, Cohen FE. Chalcone, acyl hydrazide and related amides kill cultured *Trypanosoma brucei*. Mol. Med. (N. Y.). 2000;6(8):660-669.
- Yale HL, Losee K, Martins J, Holsing M, Perry FM, Bernstein J. Chemotherapy of experimental tuberculosis. VIII. The synthesis of acid hydrazides, their derivatives and related compounds. J. Am. Chem. Soc. 1953;75:1933-1942.
- 11. Bernstein J, Lott WA, Steinberg BA, Yale HL. Chemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (Nydrazid) and related compounds. Am. Rev. Tuberc. 1952;65:357-364.
- Bernstein J, Jambor WP, Lott WA, Pansy FE, Steinberg B, Yale HL. Chemotherapy of experimental tuberculosis. VI. Derivatives of isoniazid. Am. Rev. Tuberc. 1953;67:354-365.
- Bernstein J, Jambor WP, Lott WA, Pansy F, Steinberg BA, Yale HL. Chemotherapy of experimental tuberculosis. VII. Heterocyclic acid hydrazides and derivatives. Am. Rev. Tuberc. 1953;67: 366-375.
- 14. Mansour AK, Eid MM, Khalil NSAM. Synthesis and reactions of some new heterocyclic carbohydrazides and related

compounds as potential anticancer agents. Molecules. 2003;8:744-755.

- Trepanier DL, Wagner ER, Harris G, Rudzik AD. 1,4,5,6-Tetrahydro-as-triazines.
  I. Sulfuric acid catalyzed condensation of nitriles and hydrazino alcohols. J. Med. Chem 1966;9:881-885.
- Opie TR. Preparation of benzodioxincarboxylic acid hydrazides as insecticides. Eur. Pat. Appl. EP 984,009; 2000.
- 17. Silvestrini B, Cheng CY. Preparation of 3substituted-1-benzyl-1*H*-indoles as antifertility agents. U.S. US 6,001,865; 1999.
- Tomotaki Y, Kamiya K, Abe Y. Deodorant compositions. PTC Int. Appl. WO 01 62,309; 2001.
- 19. Khalil NSAM. Synthesis of some novel *N*ribosyl-1,2,4-triazin-6(1*H*)-/ones or thiones as potential antibacterial and antifungal chemotherapeutics. Nucleosides Nucleotides Nucleic Acids. 2005;24:111-120.
- Khalil NSAM. Synthesis of novel α-Larabinopyranosides of β-lactams with potential antimicrobial activity. Nucleosides Nucleotides Nucleic Acids 2005;24:1277-1287.
- Khalil NSAM. Efficient synthesis, structure, and antimicrobial activity of some novel *N*and S-β-D-glucosides of 5-pyridin-3-yl-1,2,4-triazoles. Carbohydr. Res. 2006;341: 2187-2199.
- 22. Khalil NSAM. Novel simple efficient synthetic approach toward 6-substituted-2*H*-[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole-3thiones and first synthesis and biological evaluation of *N*-and S-β-D-glucosides of the [1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole ring system. Nucleosides Nucleotides Nucleic Acids. 2007;26:347-359.
- Khalil NSAM. First synthesis and antimicrobial activity of *N*- and S-α-Larabinopyranosyl-1,2,4-triazoles. Nucleosides Nucleotides Nucleic Acids. 2007;26:361-377.
- Khalil NSAM. N- and S-α-L-Arabinopyranosyl-[1,2,4]triazolo[3,4-b] [1,3,4]thiadiazoles. First synthesis and biological evaluation. Eur. J. Med. Chem. 2007;42:1193-1199.
- Khalil NSAM. A facile synthesis, structure, and antimicrobial evaluation of novel 4arylhydrazono-5-trifluoromethyl-2,4-dihydropyrazol-3-ones, their *N*- and *N*,O-bis-β-Dglucosides. Carbohydr. Res. 2009;344: 1654-1659.

- Khalil NSAM. Efficient synthesis of novel 1,2,4-triazole fused acyclic and 21-28 membered macrocyclic/ and or lariat macrocyclic oxaazathia crown compounds with potential antimicrobial activity. Eur. J. Med. Chem. 2010;45:5265-5277.
- Khalil NSAM. Synthesis of a novel class of 1,ω-bis/(hydrazides), (hydrazones), (1,3,4oxadiazoles) and (1,3,4-thiadiazoles) with potential antimicrobial activity. Organic Chemistry: An Indian Journal (OCAIJ) 2011;7(4):251-269.
- Khalil NSAM. Efficient Synthesis of a novel class of 1,ω-bis(triazoles) and 1,ω-bis[[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles] with potential antimicrobial activity. International Journal of Applied Chemistry (IJAC). 2011;7(2):133-157.
- Khalil NSAM. Synthesis of novel 1,ω-bis[4-[(arylcarbamothioylamino)carbamoyl]phenoxy]alkanes and 1,ω-bis[4-(4-aryl-5-thioxo-1*H*-1,2,4-triazol-3-yl)phenoxy]alkanes with potential antimicrobial activity. International Journal of Applied Chemistry (IJAC). 2011; 7(2):183-201.
- Khalil NSAM, Darwish GAMA, Mostafa FAA, Bassuony NI. Antimicrobial evaluation and structure-activity relationship (SAR) of 4-amino-4*H*-[1,2,4]-triazole-3,5-dithiol and some related 6-substituted-2*H*-[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole-3-thiones. Az. J. Pharm. Sci. 2008;37:34-48.
- Khalil NSAM, Darwish GAMA, Mostafa FAA, Abdel Rahman AS. Effect of glucosidation on the antimicrobial activity of 4-amino-4*H*-[1,2,4]-triazole-3,5-dithiol and some related 6-substituted-2*H*-[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole-3-thiones. Az. J. Pharm. Sci. 2010;41:1-17.
- Khalil NSAM, Darwish GAMA, Mostafa FAA, Abdel Rahman AS. Antimicrobial screening and structure-activity relationship (SAR) of some 1,2,4-triazole-α-L-

arabinopyranosides. Az. J. Pharm. Sci. 2010;41:146-166.

- Khalil NSAM, Mansour AK, Eid MM. Synthesis of some novel 6-benzyl(or substituted benzyl)-2-β-D-glucopyranosyl-1,2,4-triazolo[4,3-b][1,2,4]triazines as potential antimicrobial chemotherapeutics. Nucleosides Nucleotides Nucleic Acids. 2004;23:1889-1910.
- Mansour AK, Eid MM., Khalil NSAM. Selective synthesis and reactions of 6substituted-2-β-galactosyl-1,2,4-triazines of potential anticancer activity. Nucleosides Nucleotides Nucleic Acids. 2003;22:21-44.
- 35. Mansour AK, Eid MM, Khalil NSAM. Synthesis of some new 2-α-Larabinopyranosyl-1,2,4-triazines as potential antitumor chemotherapeutics. Nucleosides Nucleotides Nucleic Acids. 2003;22:1805-1823.
- Mansour AK, Eid MM, Khalil NSAM. Synthesis of some *N*-galactosides of 3-aryl-5-benzyl(or substituted benzyl)-1,2,4triazin-6(1*H*)-/ones or thiones of expected biological activity. Nucleosides Nucleotides Nucleic Acids. 2003;22:1825-1833.
- Mansour AK, Ibrahim YA, Khalil NSAM. Selective synthesis and structure of 6arylvinyl-2- and 4-glucosyl-1,2,4-triazines of expected interesting biological activity. Nucleosides Nucleotides. 1999;18:2265-2283.
- Abbas AA, Khalil NSAM. Synthesis of some new 1,3/ or 1,4-bis(glucopyranosyl-1,2,4-triazol-5-ylthio)propanes/ or butanes as potential antimicrobial agents. Nucleosides Nucleotides Nucleic Acids. 2005;24:1353-1372.
- 39. Atlas RM. Handbook of microbiology media, Paks, CRC press; 1993.
- 40. Atlas M, Brown AE, Parks LC. Laboratory Manual of experimental microbiology, New York, NY: Mosby-Year Book, Inc; 1995.

© 2017 Khalil and Mohamed; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

> Peer-review history: The peer review history for this paper can be accessed here: http://sciencedomain.org/review-history/19452